Business Description

Intercept Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
I4P.GermanyICPT.MexicoICPT.USA IPO Date
2012-10-18Description
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.46 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 3.57 | |||||
Debt-to-EBITDA | -2.4 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -4.25 | |||||
Beneish M-Score | 0.38 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2 | |||||
3-Year EBITDA Growth Rate | 21.6 | |||||
3-Year EPS without NRI Growth Rate | 22 | |||||
3-Year FCF Growth Rate | 52.4 | |||||
3-Year Book Growth Rate | 12.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 10.3 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 2.83 | |||||
9-Day RSI | 11.03 | |||||
14-Day RSI | 20.85 | |||||
6-1 Month Momentum % | 18.38 | |||||
12-1 Month Momentum % | 14.56 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.35 | |||||
Quick Ratio | 2.35 | |||||
Cash Ratio | 2.11 | |||||
Days Sales Outstanding | 35.91 | |||||
Days Payable | 3613.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.1 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 99.52 | |||||
Operating Margin % | -16.43 | |||||
Net Margin % | 70.39 | |||||
ROE % | Neg. Equity | |||||
ROA % | 41.98 | |||||
ROIC % | -49.36 | |||||
ROC (Joel Greenblatt) % | -4005.18 | |||||
ROCE % | -40.45 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 2.12 | |||||
Price-to-Owner-Earnings | 2.34 | |||||
PS Ratio | 1.44 | |||||
PB Ratio | 6.11 | |||||
Price-to-Tangible-Book | 5.97 | |||||
EV-to-EBIT | -3 | |||||
EV-to-Forward-EBIT | -13.48 | |||||
EV-to-EBITDA | -3.01 | |||||
EV-to-Forward-EBITDA | -13.93 | |||||
EV-to-Revenue | 1.33 | |||||
EV-to-Forward-Revenue | 1.26 | |||||
EV-to-FCF | -15.27 | |||||
Price-to-Median-PS-Value | 0.08 | |||||
Price-to-Net-Current-Asset-Value | 6.99 | |||||
Price-to-Net-Cash | 22.19 | |||||
Earnings Yield (Greenblatt) % | -33.33 |
How Intercept Pharmaceuticals Inc (FRA:I4P) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 299.573 | ||
EPS (TTM) (€) | 6.642 | ||
Beta | 0.98 | ||
Volatility % | 69.89 | ||
14-Day RSI | 20.85 | ||
14-Day ATR (€) | 0.516993 | ||
20-Day SMA (€) | 16.40725 | ||
12-1 Month Momentum % | 14.56 | ||
52-Week Range (€) | 10.555 - 20 | ||
Shares Outstanding (Mil) | 41.67 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Intercept Pharmaceuticals Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |
Intercept Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Intercept Pharmaceuticals Inc Frequently Asked Questions
What is Intercept Pharmaceuticals Inc(FRA:I4P)'s stock price today?
The current price of FRA:I4P is €12.65. The 52 week high of FRA:I4P is €20.00 and 52 week low is €10.56.
When is next earnings date of Intercept Pharmaceuticals Inc(FRA:I4P)?
The next earnings date of Intercept Pharmaceuticals Inc(FRA:I4P) is 2023-05-05 Est..
Does Intercept Pharmaceuticals Inc(FRA:I4P) pay dividends? If so, how much?
Intercept Pharmaceuticals Inc(FRA:I4P) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |